The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Recce Pharmaceuticals (ASX:RCE) completes dosing of the first male and female subjects in its UTI/urosepsis clinical trial at the highest concentration of R327
  • The dosing lasts 15 minutes at 3000mg and was approved by an independent safety committee unanimously to run faster
  • The company recruited a full cohort and is dosing the last remaining patients in the coming days
  • RCE shares are up 2.33 per cent, trading at 44 cents at 12:37 pm AEDT

Recce Pharmaceuticals (ASX:RCE) has completed dosing the first male and female subjects in its UTI clinical trial at the highest concentration of Recce 327 (R327).

The dosing was completed in 15-minute intervals at 3000 milligrams within Recce’s phase I/II UTI/urosepsis clinical trial, and it has been approved by an independent safety committee unanimously to be administered at a faster interval.

“To be dosing at twice the speed of the last cohort to 3000mg over 15 minutes via intravenous administration is a testament to the safety and tolerability profile of R327, another important clinical milestone for the company,” RCE CEO James Graham said.

The company recruited a full cohort and is dosing the last remaining patients in the coming days.

RCE shares were up 2.33 per cent, trading at 44 cents at 12:37 pm AEDT.

rce by the numbers
More From The Market Online
The Market Online Video

Market Close: Miners take a beating as ASX slides again

Well, the buyers weren’t exactly lining up to save the day on Thursday.

Pinnacle Minerals accelerates US tungsten strategy with upcoming initial drilling program

Pinnacle Minerals is progressing planning and permitting for an initial drilling program at the Hero tungsten…

Lion Energy obtains “very encouraging” oil indications offshore Indonesia

Lion Energy has obtained promising early results from the Bula Karang-1 exploration well in the East…

High-Tech Metals defines high-grade gold target at Dagger within Damsel gold project

High-Tech Metals has confirmed Dagger as a new gold target within its 100%-owned Mt Fisher gold…